Agomab Therapeutics vs Regeneron
Side-by-side comparison of AI visibility scores, market position, and capabilities
Nasdaq IPO Feb 2026 (~$200M raised, ~$780M valuation, ticker AGMB). Positive Phase 2a data for ontunisertib in fibrostenosing Crohn's. Phase 1 data for AGMB-447 in IPF. Gut-restricted ALK5 inhibitor.
About
Agomab Therapeutics went public on Nasdaq in February 2026, raising approximately $200 million at an ~$780 million valuation (ticker: AGMB), becoming one of the first European biotechs to list in the US in 2026. Agomab is developing ontunisertib — the only clinical-stage gut-restricted ALK5/TGFβR1 inhibitor for fibrostenosing Crohn's disease, a severe complication where intestinal fibrosis causes strictures requiring repeated surgery. The company also has AGMB-447 in Phase 1 for idiopathic pulmonary fibrosis (IPF), using lung-restricted delivery of the same mechanism.
Tarrytown NY biopharma giant; creator of Dupixent (>$14B revenue), Eylea, and Kevzara. Velocity Genome platform drives fast antibody and bispecific drug discovery.
About
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized mouse technology that dramatically accelerates the discovery of human antibodies—and has used it to produce multiple best-in-class biologics across inflammatory, oncologic, and eye diseases.\n\nRegeneron's commercial portfolio is anchored by Dupixent (dupilumab), developed with Sanofi, which has become one of the best-selling drugs globally with over $14 billion in 2024 revenues, treating atopic dermatitis, asthma, COPD, and other type-2 inflammatory conditions. Additional key products include Eylea (aflibercept) for macular degeneration and PRALUENT for cardiovascular cholesterol lowering. The company's bispecific antibody pipeline, cancer vaccines in collaboration with BioNTech, and gene therapy programs represent its next growth wave.\n\nRegeneron reported over $14 billion in annual revenue in 2024 and maintains a world-class science culture, consistently ranking among the top companies for R&D productivity and employee satisfaction. Its Tarrytown campus houses more than 10,000 employees and remains a leading independent US biopharmaceutical innovator.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.